Merck KGaA
Organization
Merck KGaA, also known as the Merck Group, is a German multinational science and technology company headquartered in Darmstadt. Founded in 1668, it is the world's oldest operating chemical and pharmaceutical company and operates across three main business sectors: Healthcare, Life Science, and Electronics.
What experts have said about Merck KGaA
1 statement · 1 positive
Merck KGaA is buying Biotechny for $73 per share in cash.
“Merck K gaa, that's the one based in Germany, is buying the global life science company for $73 a share in cash.”
Open the episode · Micron Surges; Alibaba Lower; Wendy's SoarsListen at 3:10
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Discussed alongside Merck KGaA
- Moderna
Organization · 38 episodes together · 15 shows
- Keytruda
Product · 11 episodes together · 9 shows
- MRNA
Product · 2 episodes together · 1 show
- Bio-Techne
Organization · 7 episodes together · 3 shows
- Novo Nordisk
Organization · 2 episodes together · 2 shows
- Eli Lilly and Company
Organization · 3 episodes together · 3 shows
- AstraZeneca
Organization · 2 episodes together · 2 shows
- Emily Graffeo
Person · 3 episodes together · 1 show
50 episodes featuring Merck KGaA
Stock Movers
AI deals lift Accenture and Synopsys as Moderna faces valuation test
The episode contrasts investor enthusiasm for AI-linked growth with skepticism toward Moderna’s valuation after a dramatic rally and promising cancer-vaccine data.
Oct 1, 2026 · 6 min
Bloomberg Daybreak: US Edition
Cockpit attack and Trump-Fed clash drive morning headlines
The episode connects an alarming aviation security incident with a political challenge to the Federal Reserve and fresh market pressure from oil prices.
Oct 1, 2026 · 24 min
Stock Movers
Moderna’s rally collides with valuation risk as Robinhood expands markets
The episode connects three stock moves to broader questions about biotech valuations, leveraged prediction markets, and consumers under economic pressure.
Sep 30, 2026 · 8 min
Office Hours with Prop G
Scott Galloway weighs risk, mobility, and leverage
The episode connects investing, relocation, management, negotiation, and teaching through a common question: how to preserve options when stakes rise.
Sep 28, 2026 · 39 min
Stock Movers
AI momentum lifts Meta as Gen Digital stumbles
The episode shows how product traction, takeover speculation, and clinical data can rapidly reshape investor sentiment across technology, cybersecurity, and biotech.
Sep 25, 2026 · 5 min
Stock Movers
Three stocks expose AI fervor, deal risk and biotech promise
The episode shows how product momentum, acquisition speculation and clinical data can drive sharply different market reactions in one week.
Sep 25, 2026 · 5 min
Stock Movers
Shopify, Moderna and On ride distinct catalysts
The episode shows how AI partnerships, cancer-vaccine data and expansion plans can move very different companies’ shares.
Sep 22, 2026 · 7 min
The a16z Show
Enterprise AI stalls without organizational context
The conversation separates immediate cybersecurity risks from speculative superintelligence while explaining why enterprise adoption depends on context, ontology, and deployment economics.
Sep 18, 2026 · 1h 9m
Raging Moderates with Scott Galloway and Jessica Tarlov
Tarlov makes the case for disagreement without alienation
The conversation connects democratic conflict abroad and political polarization at home to a practical question: how can people argue honestly without destroying relationships?
Sep 17, 2026 · 1h 22m
Motley Fool Hidden Gems Investing
AI leaders weigh safety against the cost of staying ahead
Calls to slow frontier AI development may reflect real safety concerns, but they also affect competition, regulation, spending, and investment decisions.
Sep 14, 2026 · 27 min
All-In with Chamath, Jason, Sacks & Friedberg
Jensen Huang argues AI progress needs guardrails, not a halt
The conversation frames AI leadership as a contest over deployment, infrastructure, and participation as much as model invention.
Sep 14, 2026 · 47 min
WSJ's Take On the Week
Biotech’s rally tests the promise of cancer breakthroughs
Investors must decide whether excitement around cancer vaccines, AI and new drug platforms reflects durable growth or inflated valuations.
Sep 13, 2026 · 32 min
Office Hours with Prop G
China turns biotech strength into strategic leverage
The episode connects a high-stakes Trump-Xi meeting with a less visible shift in pharmaceutical power that leaves the United States reliant on Chinese supply chains.
Sep 8, 2026 · 54 min
Science Friday
Personalized vaccines target melanoma’s return
The approach could make cancer vaccination more precise, but its benefits, risks, cost, and availability remain unsettled.
Sep 3, 2026 · 12 min
The a16z Show
Moderna turns tumor mutations into personalized cancer vaccines
The episode examines whether individualized mRNA treatment can move from promising melanoma results to a scalable, regulated form of cancer care.
Sep 2, 2026 · 40 min
Global News Podcast
Cancer vaccine faces a political test in America
A personalized mRNA treatment could help prevent skin cancer from returning, but its future depends on public trust and continued scientific investment.
Aug 30, 2026 · 31 min
Moonshots with Peter Diamandis
AI’s next bottleneck may be memory, not compute
The episode connects frontier-model governance and concentration risks with robotics, autonomous logistics, and biomedical advances that could reshape daily life.
Aug 29, 2026 · 2h 20m
Stock Movers
Markets punish uncertainty as cities race toward smarter growth
The episode links three sharp stock moves with a larger question: whether technology can help cities absorb rapid population growth without losing control of development.
Aug 28, 2026 · 6 min
Stock Movers
PayPal deal collapse rattles fintech as Affirm gains
The episode captures how abandoned dealmaking, consumer-credit signals, and a clinical setback are reshaping sentiment across fintech and biotech.
Aug 28, 2026 · 7 min
The Journal.
Moderna bets cancer vaccine can outlast its COVID boom
The vaccine’s melanoma results offer patients a potential new treatment while testing whether Moderna can turn mRNA expertise into a durable business.
Aug 28, 2026 · 27 min
WSJ What’s News
Meta settlement puts teen-platform safeguards under scrutiny
The settlement could reshape default settings on major social platforms while the episode connects technology, health, policy, markets, and disaster response.
Aug 26, 2026 · 9 min
Stock Movers
AI pressure reshapes software and cybersecurity stocks
The episode connects three market moves to a broader question: how artificial intelligence is changing software economics, security risks, and urban infrastructure.
Aug 25, 2026 · 7 min
Equity Mates Investing Podcast
Moderna’s melanoma vaccine tests biotech optimism
The episode connects early cancer-vaccine results and AI-driven drug discovery with the harder questions of clinical proof, portfolio construction, and timing investments.
Aug 23, 2026 · 29 min
WSJ What’s News
Markets absorb a volatile week of falling stocks and rising oil
The episode connects market-wide stress with pressure on chip stocks, shifting retail demand, healthcare gains and renewed U.S. debt concerns.
Aug 22, 2026 · 6 min
Stock Movers
Gold miners rally as earnings and cancer vaccines move markets
The episode connects commodity prices, consumer resilience, and medical breakthroughs to the companies and sectors investors are watching.
Aug 21, 2026 · 7 min
Motley Fool Hidden Gems Investing
Markets test biotech promise and AI’s trillion-dollar ambitions
The episode connects higher rates and tougher capital markets with uncertain breakthroughs, inflated private-company valuations, and mounting resistance to AI infrastructure.
Aug 21, 2026 · 43 min
Stock Movers
Moderna rallies as margin pressure hits Ubiquiti
The episode connects company-specific catalysts, executive turnover, and cost pressures with a broader look at how cities plan for rapid growth.
Aug 21, 2026 · 7 min
Marketplace
Long-term joblessness exposes the limits of economic resilience
The episode connects prolonged unemployment and worker anxiety to wider questions about public debt, health risks, consumer surveillance and economic policy.
Aug 21, 2026 · 26 min
Moonshots with Peter Diamandis
AI leaders debate OpenAI training pauses and physical hardware bottlenecks
This episode provides a rare look behind the scenes of AI development, exposing the physical memory shortages, strategic corporate pauses, and robotic breakthroughs that will dictate the pace of global automation.
Aug 21, 2026 · 2h 20m
Stock Movers
Gold miners surge and Merck hits record high on vaccine trials
Understanding the specific catalysts behind sudden stock surges helps investors identify broader trends in retail resilience, defensive commodities, and biotech breakthroughs.
Aug 21, 2026 · 7 min
Stock Movers
SK Hynix rewards investors as AI costs unsettle Asian markets
The episode connects corporate capital returns, rising AI expenses, cancer-treatment advances, and urban planning to broader shifts in Asian markets and economies.
Aug 20, 2026 · 8 min
The Headlines
Debt hits $40 trillion as war probes and cancer vaccine advance
The episode connects an escalating fiscal burden with accountability questions in Gaza and cautious hope for preventing melanoma recurrence.
Aug 20, 2026 · 10 min
Morning Brew Daily
Moderna advances personalized cancer vaccines as delivery and debt pressures mount
The episode connects a potentially important medical advance with the operational, financial, and environmental strains reshaping everyday business.
Aug 20, 2026 · 31 min
Motley Fool Hidden Gems Investing
Target, Moderna and AI Face Three Very Different Growth Tests
The episode connects a retailer’s uncertain recovery, a biotech breakthrough and worsening AI economics to the question of whether market enthusiasm can last.
Aug 20, 2026 · 20 min
The AI Daily Brief: Artificial Intelligence News and Analysis
Nine overlooked techniques reshape everyday AI workflows
The episode turns fast-moving AI features into concrete experiments, while placing them alongside consequential developments in medicine, safety, and software access.
Aug 20, 2026 · 30 min
Global News Podcast
Israel probes Gaza deaths as global crises multiply
The episode examines accountability for the deaths of Hind Rajab and rescuers while connecting the story to wars, technology, climate, and public trust.
Aug 20, 2026 · 31 min
Bloomberg Daybreak: US Edition
Trump’s Iran pressure plan tests global trade routes
The episode connects proposed sanctions and Strait of Hormuz risks with China, shipping security, borrowing costs, and the dollar’s vulnerability.
Aug 20, 2026 · 21 min
Stock Movers
SK Hynix rallies as Kuaishou absorbs AI costs
The episode connects corporate capital returns, AI spending pressure, healthcare optimism and Walmart’s expanding EV ambitions across markets.
Aug 20, 2026 · 9 min
Stock Movers
Moderna surges as retailers split on demand
The market moves show how clinical breakthroughs, tariff effects, regional growth and cautious consumers can produce sharply different investor reactions.
Aug 19, 2026 · 7 min
Stock Movers
Moderna surges as beauty beats and furniture weakness split markets
The episode contrasts a breakthrough-driven biotech rally with uneven consumer-company results, then widens the lens to technology and long-term urban planning.
Aug 19, 2026 · 6 min
Stock Movers
Corporate turnarounds meet the smart-city challenge
The episode links three company-specific market moves with a broader question about how innovation and long-term planning can manage urban growth.
Aug 19, 2026 · 6 min
WSJ What’s News
Investors shrug as U.S. debt crosses $40 trillion
The episode examines why Treasury demand remains strong even as the government’s borrowing path raises longer-term sustainability concerns.
Aug 19, 2026 · 10 min
Stock Movers
Moderna rallies as Treasuries and retailers reshape the close
The episode connects company-specific surprises with shifting bond-market policy and a broader debate over how cities adapt to rapid growth.
Aug 19, 2026 · 10 min
Morning Wire
Trump weighs surveillance, diplomacy and a vaccine breakthrough
The episode links contentious domestic policy fights with consequential developments in foreign affairs, public health and medical research.
Aug 19, 2026 · 13 min
Stock Movers
Moderna surges as beauty beats and furniture falters
The episode shows how sharply different trial results, earnings, and forecasts can redirect investor attention across sectors.
Aug 19, 2026 · 6 min
Stock Movers
Moderna surges as retailers signal diverging consumer strength
The episode contrasts a major clinical catalyst with uneven retail results, showing how company-specific news and housing weakness are reshaping market expectations.
Aug 19, 2026 · 7 min
Stock Movers
European stocks diverge as cities race toward smarter growth
The episode connects market signals from company guidance with the larger infrastructure challenge created by rapid urbanization.
Aug 13, 2026 · 6 min
Stock Movers
Palantir surges and Caterpillar climbs on data center demand
Corporate earnings are revealing which sectors are capturing the most value from the ongoing artificial intelligence and data center infrastructure buildout.
Aug 4, 2026 · 7 min
Stock Movers
AI fears sink Concentrix while lawmakers target Merck and AbbVie trials
Investors are grappling with the immediate financial impacts of AI disruption and the growing geopolitical risks of conducting pharmaceutical research in China.
Jun 30, 2026 · 6 min
Stock Movers
Biotech deal lifts one stock as AI bets unsettle two others
The episode shows how acquisitions, debt worries and IPO uncertainty can quickly reshape investor sentiment across technology and life sciences.
Jun 26, 2026 · 7 min